NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Recruiting
PHASE3Ages 18+InterventionalTreatmentRegeneron Pharmaceuticals
~270 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:LinvoseltamabDaratumumab
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria
Measured over Up to 5 years
+1 more outcome measured
Conditions
Where it's being run
2 sites across 2 statesGeorgia1
Massachusetts1
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteriaUp to 5 years
- Biochemical PFS per IMWG criteriaUp to 5 years